Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

S M Tolaney, S Sammons, A Sandoval-Leon, J Cortes, A M Liepa, B R Grimes, D He, Z L Cui, J Roose, W Gathirua-Mwangi, K Moreira, J O'Shaughnessy, P Neven, S R D Johnston, H S Rugo